Source: National Institute of Diabetes, and Digestive Diseases, and Kidney Diseases (NIDDK) of the National Institutes of Health. R01 proposal in response to RFA “Nanoscience and Nanotechnology in Biology and Medicine” program (1R01-DK080477-01).
Grant Title: Oral Gene Therapy with NiMOS for Inflammatory Bowel Disease
Duration: March, 2008 – February, 2012 [NIH RePORTER link]
Source: National Cancer Institute of the National Institutes of Health, R21 Proposal in response to RFA PAR-07-034 “Nanoscience and Nanotechnology in Biology and Medicine”. (1R21-CA135594-01A2)
Grant Title: Nano-Delivery of Mitochondria-Targeted Ceramide to Overcome Tumor Drug Resistance
Duration: January, 2010 – December, 2011 [NIH RePORTER link]
Source: National Institute of Neurological Disorders and Stroke of the National Institutes of Health, R21 Proposal in response to RFA PAR-08-232 “NINDS Exploratory/Developmental Projects in Translational Research (R21)”. (1R21-NS066984-01)
Grant Title: Multifunctional Nanoemulsions for Modulation of BBB Transport
Duration: February, 2010 – January, 2012 [NIH RePORTER link]
Source: Nemucore Medical Innovations, Inc., Sub-Contract of NCI Phase 1 SBIR grant.
Grant Title: EGFR-Targeted Nanoemulsions for Imaging and Therapy of Ovarian Cancer
Duration: September, 2010 – August, 2012
Source: National Science Foundation, Interdisciplinary Graduate Education and Training (IGERT) Grant
Grant Title: IGERT-Nanomedical Science and Technology
Duration: September, 2010 – August, 2015
Source: National Cancer Institute of the National Institutes of Health proposal in response to NCI’s Alliance for Nanotechnology in Cancer RFA CA-09-012 “Center of Cancer Nanotechnology Excellence (CCNE) U54 Grant” program (1U54-CA151881-01).
Grant Title: Multi-Modal Gene Therapy for Pancreatic Cancer with Targeted Nanovectors
Duration: September, 2010 – August, 2015 [NIH RePORTER link]
Source: National Cancer Institute of the National Institutes of Health proposal in response to the NCI’s Alliance for Nanotechnology in Cancer RFA CA-09-013 “Cancer Nanotechnology Platform Partnership U01 Grant” program (1U01-CA151452-01)
Grant Title: Combinatorial-Designed Nano-Platforms to Overcome Tumor Drug Resistance
Duration: September, 2010 – August, 2015 [NIH RePORTER link]
Source: National Cancer Institute of the National Institutes of Health proposal in response to Request for Application “Academic-Industrial Partnerships for Translation of In Vivo Imaging Systems for Cancer Investigations (R01)” PAR-10-169 (1 R01 CA158881-01)
Grant Title: Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer
Duration: April, 2011 – March, 2016 [NIH RePORTER link]